Overview
The mission of the Wellstone MDSRC of Seattle is to advance new therapies for muscular dystrophies. Our laboratories conduct basic research to deepen the understanding of disease mechanisms and pathologies, identifying novel therapeutic targets. That basic research then serves as the basis of translational and preclinical work, bridging the basic science with the clinic. Our clinicians collect natural histories and biologic samples, bridging back to the laboratories by providing necessary resources to interrogate disease processes. Meanwhile, they also assemble the infrastructure and develop the relationships with patients and their families that will be necessary to conduct clinical trials. Together, our collaborative team of MDs and PhDs position our MDSRC to both develop and test novel treatments for muscular dystrophies and related diseases.
Get in touch
Potential donors, researchers, and members of the public are welcome to contact the Seattle MDSRC.
Contact us ▸
Learn more
Learn more about the NIH Muscular Dystrophy Coordinating Committee (MDCC) and the MD-CARE Act.
MDCC website ▸
Donate
MDSRC Members
Director Jeffrey S. Chamberlain, Ph.D.
Professor, University of Washington
Areas of Interest: DMD, micro-dystrophin, AAV vector delivery, CRISPR gene therapies
Contact Information: jsc5@uw.edu | (206) 616-6645
Co-Director Stephen J. Tapscott, M.D., Ph.D.
Professor, University of Washington
Areas of Interest: FSHD, Gene Misregulation, Muscle Disease and Cancer
Contact Information: stapscot@fhcrc.org | (206) 667-4499
Research Assistant Professor, University of Washington
Areas of Interest: FSHD, MD, AAV disease models and testing, RNAi gene silencing therapies
Contact Information: jrcham@uw.edu | (206) 616-6645
Assistant Professor, University of Washington
Areas of Interest: DMD, X-liked myotubular myopathy, X-linked myopathy, AAV gene therapy, vector efficacy
Associate Professor, University of Rochester
Areas of Interest: Myotonic dystrophy, FSHD, neuromuscular clinical care, nerve and muscle diagnostic testing
Contact Information: johanna_hamel@urmc.rochester.edu | (585) 275-2559
Research Associate Professor, University of Nevada
Areas of Interest: FSHD mouse models, DUX4 gene mechanisms, accesible diagnostic testing
Contact Information: takakojones@med.unr.edu | (775) 784-7594
Research Associate Professor, University of Washington
Areas of Interest: Muscular dystrophy disease progression, dystrophin biology and pathology, genetic muscle therapies, advanced tools for disease modeling
Contact Information: godom@uw.edu | (206) 221-5412
Professor, University of Rochester
Areas of Interest: Molecular mechanisms in FSHD, periodic paralysis, treatment of neuromuscular disorders
Contact Information: Rabi_tawil@urmc.rochester.edu | (585) 275-2559
Assistant Professor, University of Washington
Areas of Interest: DMD, CRISPR gene editing, muscle stem cell therapies, genetic muscle pathology
Contact Information: niclasb@uw.edu | (206) 616-4259
Emeritus Professor, University of Washington
Areas of Interest: AAV CRISPR and gene editing, muscle development and cell culture, muscle-specific gene promoters (MSECs)
Contact Information: haus@uw.edu | (206) 616-6998
Associate Professor, University of Kansas
Areas of Interest: High dimensional data analysis, cancer and neuroimaging genetics, EHR predictive modeling
Contact Information: yli8@kumc.edu
Professor, University of Washington
Areas of Interest: Heart and muscle gene therapies, stem cells and tissue engineering, multi-scale muscle modeling
Contact Information: mregnier@uw.edu | (206) 221-0504
Associate Professor, University of Washington
Areas of Interest: Neuromuscular disease diagnosis, treatment, and care; FSHD; ALS
Contact Information: leowang@uw.edu | (206) 598-7688
Manager, Innovation Imaging and Simulation Modeling, Seattle Children's Hospital
Areas of Interest: Translational clinical care, advanced medical simulation, imaging FSHD biomarkers
Contact Information: seth.friedman@seattlechildrens.org
Professor, University of Nevada
Areas of Interest: FSHD, muscular disease mechanisms, creation of model organisms, improved diagnostics, CRISPR and drug therapies
Contact Information: peterjones@med.unr.edu | (775) 784-1566
Professor, University of Washington
Areas of Interest: Neuromuscular disease mechanisms, AAV and CRISPR gene therapies, patient stem cell models
Contact Information: dmack21@uw.edu | (206) 616-8204
Professor, University of Kansas
Areas of Interest: FSHD clinical trial design, biomarker measurement tools, patient outcome measures
Contact Information: jstatland@kumc.edu